Exam 3: NSG550/ NSG 550 (New 2024/ 2025) Diagnostic Reasoning for Nurse Practitioners Review| Questions and Verified Answers| 100% Correct| A Grade

Exam 3: NSG550/ NSG 550 (New 2024/ 2025) Diagnostic Reasoning for Nurse Practitioners Review| Questions and Verified Answers| 100% Correct| A Grade QUESTION CA 19-9, 132 Associated with cancers in the colon, stomach, and bile duct. Elevated levels of CA 19-9 may indicate advanced cancer in the pancreas but also associated with gallstones, pancreatitis, cirrhosis, and cholecystitis. Tumor marker to diagnose cancer and evaluate response to treatment. QUESTION CA 15-3 and CA 27-29 Answer: Tumor markers for breast cancer. CA27-29 more specific to breast cancer. QUESTION CA 125, 134 Answer: Tumors markers for ovarian cancer. QUESTION Carcinoembryonic antigen (CEA) Answer: determine extent of disease and prognosis in patients with cancer (GI or breast). QUESTION Mean Inhibitory Concentration (MIC) Answer: average concentration of the drug that inhibits the growth of an organism. QUESTION Cervical Screening and Bethesda result, interpretations, and f/u Answer: The Bethesda system for reporting cervical and vaginal cytologic diagnosis. Developed by Nation Cancer Institute to minimize discrepancies in result reporting and create a standardized framework for reporting results. QUESTION The Bethesda System List of terms that are universal to lab systems for reporting Pap